Novel design principle validated: Glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent

L. Somsák, V. Nagy, Sébastien Vidal, K. Czifrák, Eszter Berzsényi, Jean Pierre Praly

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

2-Naphthyl-substituted glucopyranosylidene-spiro-oxathiazole prepared following a novel design principle was found to be the best known glucose analogue inhibitor of rabbit muscle glycogen phosphorylase b (Ki 160 nM).

Original languageEnglish
Pages (from-to)5680-5683
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume18
Issue number20
DOIs
Publication statusPublished - Oct 15 2008

Fingerprint

Phosphorylase b
Glycogen Phosphorylase
Hypoglycemic Agents
Muscle
Rabbits
Glucose
Muscles
glucopyranosylidene-spiro-oxathiazole

Keywords

  • Glucose analogue
  • Glycogen phosphorylase
  • Inhibitor
  • Oxathiazole
  • Spiro-bicyclic sugar
  • Spirocyclization

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Novel design principle validated : Glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent. / Somsák, L.; Nagy, V.; Vidal, Sébastien; Czifrák, K.; Berzsényi, Eszter; Praly, Jean Pierre.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 18, No. 20, 15.10.2008, p. 5680-5683.

Research output: Contribution to journalArticle

@article{c9f983cc6b664741a90008f1cf148b64,
title = "Novel design principle validated: Glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent",
abstract = "2-Naphthyl-substituted glucopyranosylidene-spiro-oxathiazole prepared following a novel design principle was found to be the best known glucose analogue inhibitor of rabbit muscle glycogen phosphorylase b (Ki 160 nM).",
keywords = "Glucose analogue, Glycogen phosphorylase, Inhibitor, Oxathiazole, Spiro-bicyclic sugar, Spirocyclization",
author = "L. Soms{\'a}k and V. Nagy and S{\'e}bastien Vidal and K. Czifr{\'a}k and Eszter Berzs{\'e}nyi and Praly, {Jean Pierre}",
year = "2008",
month = "10",
day = "15",
doi = "10.1016/j.bmcl.2008.08.052",
language = "English",
volume = "18",
pages = "5680--5683",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "20",

}

TY - JOUR

T1 - Novel design principle validated

T2 - Glucopyranosylidene-spiro-oxathiazole as new nanomolar inhibitor of glycogen phosphorylase, potential antidiabetic agent

AU - Somsák, L.

AU - Nagy, V.

AU - Vidal, Sébastien

AU - Czifrák, K.

AU - Berzsényi, Eszter

AU - Praly, Jean Pierre

PY - 2008/10/15

Y1 - 2008/10/15

N2 - 2-Naphthyl-substituted glucopyranosylidene-spiro-oxathiazole prepared following a novel design principle was found to be the best known glucose analogue inhibitor of rabbit muscle glycogen phosphorylase b (Ki 160 nM).

AB - 2-Naphthyl-substituted glucopyranosylidene-spiro-oxathiazole prepared following a novel design principle was found to be the best known glucose analogue inhibitor of rabbit muscle glycogen phosphorylase b (Ki 160 nM).

KW - Glucose analogue

KW - Glycogen phosphorylase

KW - Inhibitor

KW - Oxathiazole

KW - Spiro-bicyclic sugar

KW - Spirocyclization

UR - http://www.scopus.com/inward/record.url?scp=53549126892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549126892&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2008.08.052

DO - 10.1016/j.bmcl.2008.08.052

M3 - Article

C2 - 18793852

AN - SCOPUS:53549126892

VL - 18

SP - 5680

EP - 5683

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 20

ER -